一期前路病灶清除植骨及内固定术治疗颈椎及颈胸段脊柱结核

目的 总结一期前路病灶清除、椎体间植骨及前路内固定治疗颈椎及颈胸段脊柱结核的临床疗效,探讨重建脊柱稳定性的必要性和安全性.方法 2002年4月-2006年3月,采用一期前路病灶清除、椎体间植骨及前路内固定治疗13例颈椎及颈胸段脊柱结核患者.男8例,女5例;年龄21～58岁.病程1～7个月,平均4个月.颈椎结核10例,颈胸段结核3例.术前X线片、CT、MRI检查示病变部位为:C3、41例,C5 2例,C5、63例,C6、74例,C7、T12例,C7～T2 1例.后凸Cobb角为20～50°,平均35.7°.神经功能ASIA分级:B级1例,C级4例,D级6例,E级2例.术前血沉34～78 ram/h,平均42 mm/b.结果 术后患者均获随访,随访时间9～34个月,平均14个月.均未出现伤口深部感染或窦道形成,平均1.5个月血沉降至20mm/h以下.患者植骨均完全融合,融合时间3～5个月,平均3.4个月.术后后凸Cobb角17～390,平均29.30;随访14个月时为9～21°,平均14.5°.神经功能除1例B级恢复至D级外,余均达E级.结论 一期前路病灶清除同期植骨内固定治疗颈椎及颈胸段脊柱结核能彻底清除病灶、防止复发、矫正畸形、重建脊柱稳定性,促进脊柱植骨融合,提高脊柱结核的治愈率.     

前后路联合手术治疗多节段颈胸段脊柱结核

目的探讨前后入路联合手术治疗多节段颈胸段脊柱结核的效果。方法对2003年以来8例患C6～T3椎体结核的病例，抗结核治疗2周后，进行前路病灶清除植骨术联合后路椎弓根固定术治疗，观察脊柱稳定性及脊髓功能恢复情况。结果所有患者经术后随访植骨部位均骨性愈合，感觉、运动功能均有不同程度改善，胸背部疼痛或不适明显缓解，无复发，近期疗效均较满意。结论前路手术可有效清除病灶、植骨，后路手术可固定多节段颈胸段脊柱，前后路联合治疗多节段颈胸段脊柱结核效果满意。     

一期前后路联合手术治疗颈胸段多节段脊柱结核

目的一期前后路联合手术治疗颈胸段脊柱结核并对其临床疗效进行评价。方法2007年3月-2008年3月5例颈胸段脊柱结核患者行一期颈椎后路人工骨植骨及钉棒系统内固定联合前路病灶清除及髂骨植骨钛板内固定术。术后继续抗结核治疗〉9个月。结果手术出血量为325mL±25mL。5例均获得随访,随访时间为12—15个月,随访期间均未见结核复发和内固定失败。脊髓及神经根压迫症状均有不同程度的改善,JOA评分由术前的10．6±1．2分提高到术后的15．2±0．7分。结论一期前后路联合手术治疗颈胸段多节段脊柱结核可获得满意的初期疗效。病灶的彻底清除、360°的植骨、前后联合内固定以及系统的抗结核治疗均是获得满意疗效的关键。     

一期前后路联合手术治疗颈胸段多节段脊柱结核

【摘要】 目的 一期前后路联合手术治疗颈胸段脊柱结核并对其临床疗效进行评价。 方法 2007年3月~2008年3月5例颈胸段脊柱结核患者行一期颈椎后路人工骨植骨及钉棒系统内固定联合前路病灶清除及髂骨植骨钛板内固定术。术后继续抗结核治疗＞9个月。 结果 手术出血量为325 mL±25 mL。5例均获得随访,随访时间为12～15个月,随访期间均未见结核复发和内固定失败。脊髓及神经根压迫症状均有不同程度的改善,JOA评分由术前的10.6±1.2分提高到术后的15.2±0.7分。 结论 一期前后路联合手术治疗颈胸段多节段脊柱结核可获得满意的初期疗效。病灶的彻底清除、360°的植骨、前后联合内固定以及系统的抗结核治疗均是获得满意疗效的关键。     

一期病灶清除、植骨及前路短节段固定治疗胸腰椎结核

目的探讨一期病灶清除、植骨及前路短节段固定治疗胸腰椎结核的疗效。方法本组33例采用前路病灶清除、植骨短节段固定治疗脊柱结核,手术前正规化疗2~4周,调整内科疾病,行病灶刮除,清除病变椎间盘,自体大块骼骨块或肋骨条植骨,侧前方安装内固定系统,尽可能安装在病椎上,术后正规抗痨治疗1~2年。结果全部病例伤口均一期愈合,术后随访1～4年,全部病例植骨均获完全骨性愈合,术后平均随访32个月未见脊柱结核复发。结论一期病灶清除、植骨及前路短节段固定治疗胸腰椎结核具有一次性完成手术,清除病灶彻底,手术时间短、出血少、内固定器械操作相对简单,创伤小,融合率高,复发率低等优点。     

前路一期病灶清除植骨内固定治疗胸腰椎结核的疗效观察

目的:探讨胸腰椎结核前路一期病灶清除、植骨内固定手术治疗的效果。方法:1996年4月~2000年8月采用前路一期病灶清除植骨内固定治疗胸腰椎结核患者56例,随访46例,观察术后和随访时神经功能恢复、畸形纠正、结核治愈率、植骨融合及并发症情况。结果:术后6个月时骨性融合率60%;12~18个月时90%融合;2年时100%融合。在胸段、胸腰段及腰段后凸畸形分别平均纠正19°、10°及9°,随访时无矫正度丢失;11例伴截瘫者神经功能平均恢复2级(Frankel分级);结核治愈率100%。并发症有继发结核性胸膜炎1例,相邻节段继发结核1例,均经抗结核化疗治愈。结论:脊柱前路一期病灶清除植骨内固定治疗胸腰椎结核具有能矫正后凸成角畸形、预防畸形复发、术后患者能早期离床活动等优点,治疗效果满意。     

一期侧前方入路病灶清除植骨双钉棒系统内固定治疗胸腰椎脊柱结核

目的探讨前路一期侧前方入路病灶清除、自体髂骨植骨融合、双钉棒系统内固定治疗胸腰椎脊柱结核的临床疗效。方法对35例胸腰椎脊柱结核患者术前常规抗结核治疗2~3周,待全身状态改善后均采用一期前路结核病灶清除、髂骨椎间植骨融合、双钉棒内固定手术。术后继续系统抗结核治疗12~18个月。记录手术时间、术中出血量、并发症、植骨融合情况,比较术前、术后3个月及末次随访时VAS评分、Cobb角、ESR、CRP,观察末次随访时脊髓神经功能ASIA分级改善情况。结果手术时间120~225 min,术中出血量450~1 060 ml。术中及术后无严重并发症发生。患者均获得随访,时间12~22个月。术中切除病灶组织经病理检查均符合结核改变。末次随访时患者结核症状均消失,ESR及CRP恢复正常。植骨融合时间8~12个月。随访期间患者无移位、松动、断裂等并发症发生。末次随访神经功能ASIA分级:1例B级者恢复至C级,4例C级者3例恢复至D级、1例恢复至E级,18例D级者均恢复至E级。结论在全身有效标准化抗结核治疗基础上,一期前路结核病灶清除、髂骨植骨融合、双钉棒内固定手术治疗胸腰段脊柱结核疗效满意,有利于神经功能恢复,可矫正后凸畸形,恢复脊柱生物力学稳定性。     

前路一期病灶清除植骨内固定治疗胸椎及胸腰段脊柱结核并不全瘫

目的 探讨前路一期病灶清除联合植骨融合内固定治疗胸椎及胸腰段脊柱结核合并不全瘫痪的治疗效果.方法 对16例胸椎及胸腰段脊柱结核并脊髓损伤致不完全瘫痪的患者经胸或胸腹前路行一期病灶清除、椎间肋骨(钛网)植骨、椎体行内固定术.术后正规四联化疗方案治疗.结果 患者切口均一期愈合.16例均获随访,时间12 ～60个月.植骨部分融合时间为3～8个月,到末次随访时植骨全部融合.后凸畸形明显改善.无钛网移位及内固定松动发生.结论 经胸及胸腹前路一期病灶清除联合肋骨(钛网)植骨及内固定治疗胸椎及胸腰段脊柱结核合并不全瘫痪疗效满意.     

一期后路固定前路病灶清除植骨治疗胸腰椎结核

目的探讨一期后路椎弓根钉系统内固定前路病灶清除植骨治疗胸腰椎结核的临床疗效。方法2001年2月至2007年7月治疗胸腰段及腰椎结核18例,男11例,女7例,平均年龄36.7岁,平均病程9个月,均为初治患者。T11-L2节段10例,L3-58例,病变位于1个节段者7例,2个节段11例,术前Cobb′S角23°69,°平均38.3°。均采用一期后路椎弓根钉系统内固定,前路经胸腹膜外入路病灶清除植骨,术前术后抗结核药物治疗。结果所有患者切口均一期愈合,术后拍片显示植骨及内固定物位置良好,Cobb′S角平均14.30。18例患者获平均25个月随访,植骨均在4-6个月达骨性融合,无内固定物松动及断裂,Cobb′S角平均15.1,°无明显矫正角度丢失,脊髓功能恢复良好,按F rankel分级,术前C级3例,术后恢复到D级1例,E级2例,D级4例均恢复至E级。无结核复发。结论一期后路椎弓根系统内固定,前路病灶清除植骨治疗胸腰椎结核,在病变节段稳定的情况下实施病灶清除植骨,有利于前路手术的操作安全,避免植骨块的松动、脱出,植骨稳定,融合率高,能有效矫正后凸畸形。     

多节段脊柱结核的手术方式选择

目的：根据多节段脊柱结核的临床特点探讨其手术方式选择。方法：对1997年4月～2006年4月我科手术治疗的82例多节段脊柱结核患者进行回顾性分析。颈椎结核6例，颈胸段结核11例，胸椎结核35例，腰椎结核21例，腰骶段结核9例，其中远距离跨阶段的跳跃性脊柱结核6例，采用一期前路病灶清除植骨融合内固定64例，一期前后路病灶清除植骨融合内固定16例，分期手术5例。结果：平均手术时间180min（90-280min），平均出血量750m1（400～2100ml）。术后胸腔积液1例，短暂性神经损伤2例。随访3-26个月，刀口延迟愈合3例，除1例外脊髓受累患者神经功能明显恢复，无内固定松动、断裂。未见结核病灶复发。结论：根据多节段脊柱结核病理破坏程度部位，病灶清除、植骨融合内固定手术是一种安全、有效的外科治疗方式。     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Anterior Interosseous Nerve Palsy After Shoulder Arthroscopy Treated With Surgical Decompression: A Case Series and Systematic Review of the Literature

Background: Anterior interosseous nerve (AIN) palsy is a very uncommon cause of upper extremity pain and weakness that comprises less than 1% of all upper extremity nerve palsies. Rarely reported but also mentioned in the literature is AIN palsy after shoulder arthroscopy. Methods: A systematic review of the literature to date using PubMed was conducted to identify patients who suffered AIN palsy after shoulder arthroscopy procedures. Articles included met the following criteria: (1) published in English; (2) primary presentation of the data; (3) patients had undergone shoulder arthroscopy before developing symptoms of AIN palsy; and (4) diagnosis was confirmed with clinical symptoms of AIN palsy. Measured outcomes included patient demographics, specific shoulder procedure, anesthesia procedure, intra-operative patient positioning, intra-operative compressive dressing, intra-operative traction, surgical versus conservative treatment, abnormal findings during decompression procedure, proposed mechanism of injury, and follow-up. Results: The search yielded 6 articles, of which 4 (13 cases) met inclusion criteria. An additional 2 cases were included in this report totaling 15 cases. The average patient age was 49 years (range: 31-64) with 73% males. At average follow-up of 24 months, 67% of patients experienced complete resolution of symptoms—more than half of which underwent surgical decompression. Patients who failed to progress experienced weakness of the flexor digitorum profundus and flexor pollicis longus muscles. Conclusions: Proposed injury mechanisms for AIN palsy after shoulder arthroscopy range from mechanical trauma, compressive hematoma, and direct anesthetic neurotoxicity. Management should be directed by clinical symptoms, imaging, and patient factors with majority of patients expected to have excellent clinical outcomes.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Fluorescence in the Sclera,Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood’s light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood’s light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood’s light even two months after its cessation.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系

目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。     

Factors Associated With Reoperation After Silicone Proximal Interphalangeal Joint Arthroplasty

Background: Silicone proximal interphalangeal (PIP) joint arthroplasty has a high revision rate. It has been suggested that persistent ulnar deviation and joint instability influence the durability of PIP silicone arthroplasties. The goal of this study was to evaluate what factors are associated with reoperation after silicone PIP arthroplasty. Methods: We retrospectively evaluated all adult patients who underwent PIP silicone arthroplasty between 2002 and 2016 at one institutional system for inflammatory-, posttraumatic-, and primary degenerative arthritis. After manual chart review, we included 91 patients who underwent 114 arthroplasties. Fingers operated included 14 index, 41 middle, 38 ring, and 21 small fingers. Results: The overall reoperation rate was 14% (n = 16). Non-Caucasian race (P = .040), smoking (P = .022) and PIP silicone arthroplasty for post-traumatic osteoarthritis (P = .021) were associated with reoperation. The 1-, 5- and 10-year implant survival rates were 87%, 85%, and 85%, respectively. Conclusion: Caution should be exercised when considering PIP silicone arthroplasty of the index finger or in patients with post-traumatic osteoarthritis. It may be worthwhile addressing smoking behavior before pursuing silicone PIP arthroplasty.